🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

68 results for “Lxo” Clear

  1. Bone marrow mesenchymal stem cells autologous

    Lxo Ireland Designated Activity Company

    Multiple Sclerosis

    phase 2 other completed

    1 trial

  2. Bone marrow mononuclear cells

    Lxo Ireland Designated Activity Company

    Chronic Myocardial Ischemia

    phase 2 other completed

    1 trial

  3. CMB305

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 mab terminated

    2 trials

  4. Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.

    Lxo Ireland Designated Activity Company

    Liver Transplant Rejection

    phase 2 other completed

    1 trial

  5. Combination of MK3475 with Metronomic CP

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 small molecule completed

    1 trial

  6. Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Graft Versus Host Disease

    phase 2 other completed

    1 trial

  7. DT-168

    Lxo Ireland Designated Activity Company

    Fuchs Endothelial Corneal Dystrophy

    phase 2 small molecule active

    1 trial

  8. DT-216P2

    Lxo Ireland Designated Activity Company

    Friedreich Ataxia

    phase 2 small molecule active

    2 trials

  9. G100

    Lxo Ireland Designated Activity Company

    Follicular Low Grade Non-Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  10. Gabapentin

    Lxo Ireland Designated Activity Company

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  11. Hyperimmune plasma

    Lxo Ireland Designated Activity Company

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  12. IMD-1041

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  13. Infusion of MSC

    Lxo Ireland Designated Activity Company

    Discordant Immunological Response in HIV Infected Subjects

    phase 2 small molecule completed

    1 trial

  14. Infusion of autologous mononuclear bone marrow cells

    Lxo Ireland Designated Activity Company

    Idiopathic Dilated Cardiomyopathy

    phase 2 small molecule terminated

    1 trial

  15. Infusion of mesenchymal stem cells from adipose tissue

    Lxo Ireland Designated Activity Company

    Faecal Incontinence

    phase 2 small molecule completed

    1 trial

  16. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  17. Intraarterial infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 other completed

    2 trials

  18. Intracoronary infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Dilated Cardiomyopathy

    phase 2 other completed

    1 trial

  19. Intravenous administration of 1 million of MSC

    Lxo Ireland Designated Activity Company

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  20. Mesenchymal stem cells from adipose tissue

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia

    phase 2 other completed

    1 trial

  21. PHITAH

    Lxo Ireland Designated Activity Company

    Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  22. Stem cell infusion

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule terminated

    1 trial

  23. implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).

    Lxo Ireland Designated Activity Company

    Cleft Lip and Palate

    phase 2 other active

    1 trial

  24. 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HPV Infection

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources